Improving quality of life through innovations in urology.
Get news and information for
healthcare professionals
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Appoints James Hindman to...
on May 27, 2020
James Hindman , a veteran global and strategic senior financial executive, brings extensive […]
Read Latest Post -
Urovant Sciences to Present at the Jefferies...
on May 26, 2020
IRVINE, Calif. and BASEL, Switzerland --(BUSINESS WIRE)--May 26, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post -
Urovant Sciences Presents Positive Clinical...
on May 14, 2020
52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained […]
Read Latest Post
View more
Copyright 2018 © All Rights Reserved